[
  {
    "categoryName": "Medicines",
    "groups": [
      {
        "group": "CAR-T",
        "items": [
          {
            "item": "Kymriah",
            "description": "(Novartis) First CAR-T ever approved by FDA in Aug 2017",
            "details": {
              "Indications": "Initially approved for pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL). Later it also got approved for adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy.>",
              "Notes": "xxxxxxxxxxxxxxxxxxxxx"
            },
            "collapsible": true
          },
          {
            "item": "Yescarta",
            "description": "(Gilead) 2nd US approved CAR-T in Oct 2017, cleared for several B-cell lymphomas including DLBCL & follicular lymphoma. 2022 won earlier use in lymphoma",
            "details": {
              "Indications": "Cleared for several B-cell lymphomas including DLBCL & follicular lymphoma. 2022 won earlier use in lymphoma.",
              "Notes": "xxxxxxxxxxxx"
            },
            "collapsible": true
          },
          {
            "item": "Tecartus",
            "description": "(Gilead) 3rd CAR-T approved in July 2020, first for mantle cell lymphoma, extended to acute lymphoblastic leukemia",
            "details": {
              "Indications": "First for mantle cell lymphoma, extended to acute lymphoblastic leukemia",
              "Notes": "xxxxxxxxxxxxxxxxxxxxxxxx"
            },
            "collapsible": true
          },
          {
            "item": "Breyanzi",
            "description": "(Bristol Myers) 4th CAR-T approved in Feb 2021",
            "details": {
              "Indications": "for types of large B-cell lymphoma",
              "Notes": "xxxxxxxxxxxxxxxxxx"
            },
            "collapsible": true
          },
          {
            "item": "Abecma",
            "description": "(Bristol Myers) 5th CAR-T approved in Mar 2021, 1st for multiple myeloma",
            "details": {
              "Indications": "xxxxxxxxxxxxxxxxxx",
              "Notes": "Targets B-cell maturation antigen (BCMA)."
            },
            "collapsible": true
          },
          {
            "item": "Carvykti",
            "description": "(J&J/Legend Biotech) 6th CAR-T approved in Feb 2022, 2nd for multiple myeloma",
            "details": {
              "Indications": "xxxxxxxxxxxxxxxxxxxxx",
              "Notes": "Approved in Feb 2022. Targets BCMA."
            },
            "collapsible": true
          }
        ]
      },
      {
        "group": "Bispecific antibodies",
        "items": [
          {
            "item": "Blincyto",
            "description": "First to win approval in 2014.",
            "details": {
              "Maker": "Amgen",
              "Notes": "These bispecific drugs work by binding simultaneously to proteins on tumor cells and on T cells, inducing an immune attack on cancer. The first drugs to gain approval treated leukemia and lymphoma based on protein targets distinctive to those diseases."
            },
            "collapsible": false
          },
          {
            "item": "Hemlibra",
            "description": "2nd bispecific antibody approved in U.S.",
            "details": {
              "Maker": "Roche",
              "Notes": "Binds to two proteins important in blood clotting to help stem bleeding in people with hemophilia. Targets: CD19 x CD3"
            },
            "collapsible": false
          },
          {
            "item": "Rybrevant",
            "description": "3rd bispecific antibody approved in U.S. in May 2021",
            "details": {
              "Maker": "J&J",
              "Notes": "The FDA approved Rybrevant to treat a specific mutation in a cancer-linked protein that’s thought to be present in about 2% of patients with non-small cell lung cancer. Targets: EGFR x cMET"
            },
            "collapsible": false
          },
          {
            "item": "Vabysmo",
            "description": "Approved in Jan 2022, fourth FDA-approved therapy for “wet” age-related macular degeneration",
            "details": {
              "Maker": "Roche",
              "Notes": "4th FDA-approved therapy for “wet” age-related macular degeneration. VEGF x Ang-2"
            },
            "collapsible": false
          },
          {
            "item": "Tecvayli",
            "description": "Approved in Oct 2022, first-of-its kind for multiple myeloma",
            "details": {
              "Maker": "J&J",
              "Notes": "Targets BCMA x CD3. One of a wave to target this protein found on malignant cells in multiple myeloma. GlaxoSmithKline was the first to target BCMA with an antibody-drug conjugate Blenrep OK'd in 2020. The CAR-T Abecma also targets BCMA. Tecvayli was J&J's 4th approved treatment for multiple myeloma."
            },
            "collapsible": false
          },
          {
            "item": "Epkinly",
            "description": "Approved in May 2023",
            "details": {
              "Maker": "AbbVie",
              "Notes": "Relapsed or refractory diffuse large B-cell lymphoma (DLBCL). CD20 x CD3"
            },
            "collapsible": false
          },
          {
            "item": "Lunsumio",
            "description": "Approved in Dec 2022",
            "details": {
              "Maker": "Roche",
              "Notes": "Follicular lymphoma. CD20 x CD3"
            },
            "collapsible": false
          },
          {
            "item": "Talquetamab",
            "description": "Experimental",
            "details": {
              "Maker": "J&J",
              "Notes": "Targets GPR5CD x CD3"
            },
            "collapsible": false
          }
        ]
      },
      {
        "group": "RSV vaccines",
        "items": [
          {
            "item": "Abrysvo",
            "description": "FDA considering for adults and maternal use in 2023.",
            "details": {
              "Maker": "Pfizer",
              "Notes": "Advisers voted 14-0 and 10-4 (safety for infant use and a closer 7-4 for older adults use in separate 2023 votes, approvals due August and May, respectively."
            },
            "collapsible": false
          },
          {
            "item": "Arexvy",
            "description": "First RSV vaccine to win U.S. approval, in May 2023.",
            "details": {
              "Maker": "GSK",
              "Notes": "Cleared only for use in adults 60 years or older."
            },
            "collapsible": false
          }
        ]
      },
      {
        "group": "Viral vectors",
        "items": [
          {
            "item": "AAV",
            "description": "adeno-associated virus. Single stranded DNA",
            "details": {
              "Integration": "Episomal, with 0.1% genomic. You can't say liver directed AAV gene therapy will be permanent, doesn't survive cell division or apoptosis. Max insertion size: Less than 8kb",
              "Notes": "XXXXXXXXXXXXXXXXXXXXX"
            },
            "collapsible": false
          },
          {
            "item": "Adenovirus",
            "description": "double stranded DNA",
            "details": {
              "Integration": "Episomal. Short term effect of 1-2 weeks. 5kb"
            },
            "collapsible": false
          },
          {
            "item": "Lentivirus",
            "description": "RNA",
            "details": {
              "Integration": "Genomic. Life-long transgene expression. 8-12kb"
            },
            "collapsible": false
          },
          {
            "item": "Herpes Simplex Virus",
            "description": "double stranded DNA",
            "details": {
              "Integration": "Episomal. Targets are CNS, muscle, heart, liver. Large packaging capacity between 30-50kb",
              "Examples": "Krystal Biotech's Vyjuvek, first topical gene therapy OK'd in May 2023, for \"butterfly children\" with dystrophic epidermolysis bullosa."
            },
            "collapsible": false
          }
        ]
      },
      {
        "group": "Gene therapy for inherited disease",
        "items": [
          {
            "item": "Zolgensma",
            "description": "xxxxxxxxxxx",
            "details": {
              "Maker": "Novartis",
              "Notes": "xxxxxxxxxxxxxxxxxxxxx"
            },
            "collapsible": false
          },
          {
            "item": "Luxturna",
            "description": "xxxxxxxxxxxxxxxxxxxxx",
            "details": {
              "Maker": "Novartis",
              "Notes": "xxxxxxxxxxxxxxxxxxxxx"
            },
            "collapsible": false
          },
          {
            "item": "Zynteglo",
            "description": "xxxxxxxxxxxxxxxxxxxxx",
            "details": {
              "Maker": "xxxxxxxxxxxxx",
              "Notes": "xxxxxxxxxxxxxxxxxxxxx"
            },
            "collapsible": false
          },
          {
            "item": "Skysona",
            "description": "xxxxxxxxxxxxxxxxxxxxx",
            "details": {
              "Maker": "xxxxxxxxxxxxx",
              "Notes": "xxxxxxxxxxxxxxxxxxxxx"
            },
            "collapsible": false
          },
          {
            "item": "Hemgenix",
            "description": "xxxxxxxxxxxxxxxxxxxxx",
            "details": {
              "Maker": "xxxxxxxxxxxxx",
              "Notes": "xxxxxxxxxxxxxxxxxxxxx"
            },
            "collapsible": false
          },
          {
            "item": "Vyjuvek",
            "description": "first topical (and redosable) gene therapy, for dystrophic epidermolysis bullosa. Sixth GT for inherited approved.",
            "details": {
              "Maker": "Krystal Biotech",
              "Notes": "Approved May 2023"
            },
            "collapsible": false
          }
        ]
      }
    ]
  }
]
